RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2007; 98(03): 702-704
DOI: 10.1160/TH07-02-0142
DOI: 10.1160/TH07-02-0142
Letters to the Editor
Haemostatic proteins gene polymorphisms in patients with unusual vein thrombosis and Ph-myeloproliferative disorders
Autoren
Financial support:The study was supported in part by the Italian MUR grants.
Weitere Informationen
Publikationsverlauf
Received
23. Februar 2007
Accepted after resubmission
07. Juni 2007
Publikationsdatum:
28. November 2017 (online)
-
References
- 1 Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
- 2 Kralovics R, Passamonti F, Buster AS. et al. A gainof- function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
- 3 Wolanskyj AP, Lasho TL, Schwager SM. et al. JAK2 mutation in essential thrombocythemia: clinical association and long-term pronostic relevance. Br J Haematol 2005; 131: 208-213.
- 4 Vanelli C, Biondi ML, Turri O. et al. SDF1–3’A gene polymorphism: risk factor for thrombotic events in Philadelphia –negative chronic myeloproliferative disorders. Haematologica 2005; 90 (Suppl. 03) 66.
- 5 Gardellini A, Biondi ML, Turri O. et al. Endothelial nitric oxide syntetase gene polymorphisms (G894T and T786C) in essential thromboythemia. Haematologica 2005; 90 (Suppl. 03) 66.
- 6 Afshar-Karghan V, Lopez JA, Gray LA. et al. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis 2004; 15: L21-24.
- 7 Denninger MH, Chait Y, Casadevall N. et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587-591.
- 8 Randi NL, Sartori MT, Luzzatto G. et al. Thrombocythosis and recurrent hepatic outflow obstruction (Budd-Chiari syndrome) after successful thrombolysis: case report and literature review. Clin Appl Thromb/Hemost 2002; 8: 369-374.
- 9 Wang SY, Wei YF, Li JD. The relationship between beta fibrinogen gene-455G/A polymorphisms and Budd-Chiari syndrome. Zhonghua Nei Ke Za Zhi 2004; 43: 753-755.
- 10 Tirado I, Soria MJ, Mateo J. et al. Association after linkage analysis indicates that homozygosity for 46 C/T polymorphism in F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost 2004; 91: 899-904.
- 11 Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999; 36: 9-13.
- 12 Randi ML, Putti MC, Scapin M. et al. Clonality status and Jak 2 V617F mutation in children with essential thrombocythemia . Blood 2006; 108: 3600-3602.
- 13 Campbell PJ, Scott LM, Buck G. et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on Jak2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953.
- 14 Goerttler PS, Steimle C, Marz E. et al. The Jak2V617F mutation, PRV-1 over-expression and EEC formation define a similar cohort of MPD patients. Blood 2005; 106: 2862-2864.
- 15 Harrison CN, Gale RE, Machin SJ. et al. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999; 993: 417-424.